Navigation Links
Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program
Date:5/5/2011

MILFORD, Mass., May 5, 2011 /PRNewswire/ -- Spring Bank Pharmaceuticals today announced it has been awarded an RO1 grant from the National Institute of Health, National Institute of Allergy and Infectious Diseases for the development of SB 9200, a novel, orally bioavailable agent for the treatment of Hepatitis B virus infection.  

Under the terms of this award, Spring Bank Pharmaceuticals will receive $3.9 million over five years in support of its development efforts.  This is the fourth Federally funded grant award Spring Bank Pharmaceuticals has received in support of it's Small Nucleic Acid Hybrid (SMNH) technology and brings the Company's total Federal support to more than $12 million.

"We are very pleased to receive this important grant award from the NIH to further develop SB 9200 for the treatment of Hepatitis B virus infections," said Douglas Jensen, CEO of Spring Bank Pharmaceuticals. " Hepatitis B infection is very widespread and has proven to be a very difficult disease to treat.  The NIH has made it clear that new types of drugs to treat Hepatitis B, such as SB 9200, are urgently needed."  According to R. P. Iyer, Ph.D., Chief Scientific Officer of Spring Bank Pharmaceuticals, "The NIH support for our HBV program validates our novel approach to treat this widespread disease.  SB 9200 holds great promise because it is a new class of potent orally bioavailable drug that works by an entirely novel mechanism of action and has demonstrated an excellent safety profile in a battery of in vitro and in vivo toxicology studies."

About Hepatitis B

Hepatitis B virus ("HBV") infects roughly one-third of the world's population, or more than two billion people. Of these, about 350 million become chronically infected, leading to progressive liver disease and approximately one million deaths each year.  Chronic infection with HBV can lead to the development of hepatocellular carcinoma ("HCC"), which has a five-year survival rate of less than 5%. Worldwide, there are about 1.2 million new cases of HCC annually, including about 15,000 in the US.

Despite the development of numerous antiviral drugs for HBV and HCV, effective treatment of hepatitis remains a substantially unmet medical need.  New treatment options are needed because current therapies do not eradicate the infection, suffer from the emergence of resistance and are poorly tolerated by many patients. SB 9200 is a potential breakthrough drug for the treatment of Hepatitis B because it has both direct antiviral and immune stimulating activities and acts via a novel host target. Further, SB 9200 is delivered orally, is well tolerated and can be used in combination with other classes of antivirals. By virtue of unique mechanism of action, SB 9200 is also being developed as novel treatment for Hepatitis C virus infection.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our proprietary platform technology, we are developing a pipeline of products representing a new class of pharmaceuticals, called Small Molecule Nucleic Acid Hybrids (SMNH) which have a wide range of therapeutic applications having multi-billion dollar market potential.  http://www.springbankpharm.com

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Contact: Don Mitchell (508) 473-5993 ext.102


'/>"/>
SOURCE Spring Bank Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
2. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
3. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
4. Discoverys Edge Spring Issue - http://discoverysedge.mayo.edu
5. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
6. Cold Spring Publishing Announces the Launch of a New Oncology Publication: The Journal of the Advanced Practitioner in Oncology
7. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
8. Cold Spring Publishing, LLC, Changes Name to Harborside Press, LLC
9. Internal Fixation Systems to Sponsor and Exhibit at Wallstreet Spring Break Growth and Value Investor Conference in Fort Lauderdale, FL March 3-4, 2010
10. US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others
11. Tahoma, Colorado Springs and Salt Lake City Have the Highest Percentage of HIV Patients in the U.S. Who Are Left Untreated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):